This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: None, Subject name: Medicine
[{'content': 'Antibody in asthma treatment \nSelect and explain. \nA. Rituximab, B. Transtusuzumab, C. Omalizumab, D. Daclizumab', 'role': 'user'}, {'content': 'Answer: C \nExplanation: Omalizumab o Omalizumab is an anti IgE agent approved by the (FDA)\nfor use in patients age 12 and above with moderate to severe persistent allergic asthma with\n: - An IgE level of30-700 lu/ml. Positive allergen skin or specific IgE tests to a perenmial allergen and Incomplete symptom control\nwith inhaled glucocorticoid treatment. o Omalizumab is administered by “subcutaneous injecon ” every mo to four weeks in a dose that\nis determined by- body weights and the level of serum IgE.\no Omalizumab produces 25% reduction in rate of asthma exacerbations.\n\xa0The response to omalizumab therapy is variable and dif icult to predict with overall response rates in patients with moderate to severe asthma averaging 30-50%.\n\xa0A minimum of 12 weeks of treatment is necessary to determine the efficacy 1 ofanti-IgE theraphy', 'role': 'assistant'}]